CRMA-1001 is a liver-targeted epigenetic therapy developed as a potential functional cure for chronic Hepatitis B (HBV) and Hepatitis D (HDV). CRMA-1001 does not modify the underlying DNA sequence but instead uses a CRISPR-Cas-based epigenetic editor to directly methylate and silence viral cccDNA and intDNA, halting viral replication and viral antigen production.
Disease: Chronic Hepatitis B, (NCT07200193)
To see all details you need to have a subscription token. Click here for more details
Candidate summary:
Disease/Disease category:
- Viral infectious diseases
Official title:
A Multi-Center, Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Adults With Chronic Hepatitis B
Phases:
- Phase 1
- Phase 2
Status:
Active recruiting
Country:
- China
- New Zealand
- United Kingdom
- Hong Kong SAR of China
